Ambu CEO expects sales in China to reach US levels
After a two-year wait, the Danish medtech group Ambu can now launch its major hope, aScope 3, on the Chinese market. CEO Lars Marcher expects to see a sales pattern similar to the one on the US market, while he expects pricing to be very different.
BY LONNI LYNGE
Good things come to those who wait and for the Danish-based medical device maker Ambu, it means approval of the company’s single-use video scope aScope 3 for the Chinese market – an approval that has been a few years coming.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Coloplast and Ambu team up
For abonnenter
Ambu CEO: our formula fits well with the hospital market
For abonnenter
